Samsung Biologics bumps Hyundai from Korean market's top 3 - Nikkei Asia
Samsung Biologics, Kineta Enter Development And Manufacturing Agreement | Contract Pharma
Samsung Pharmaceutical Arm Samsung BioLogics Fined For $4 Billion Accounts Breach
Company News | Newsroom | SAMSUNG BIOLOGICS
Enzolytics and Samsung Biologics Announce Development and Manufacturing Agreement for Anti-HIV and Anti-SARS-CoV-2 Monoclonal Antibody Therapies | World Pharma Today
Regulator punishes Samsung Pharma for making drugs in unapproved processes < Pharma < Article - KBR
Company News | Newsroom | SAMSUNG BIOLOGICS
Samsung Biologics new IPO could be valued at $2.6 billion - Medical Design and Outsourcing
GSK partners with Samsung Biologics to secure additional manufacturing capacity for innovative biopharmaceutical portfolio | World Pharma Today